The ten-eleven translocation (TET) family of methylcytosine dioxygenases initiates demethylation of DNA and is associated with tumorigenesis in many cancers; however, the mechanism is mostly unknown. Here we identify upstream activators and downstream effectors of TET1 in breast cancer using human breast cancer cells and a genetically engineered mouse model. We show that depleting the architectural transcription factor high mobility group AThook 2 (HMGA2) induces TET1. TET1 binds and demethylates its own promoter and the promoter of homeobox A (HOXA) genes, enhancing its own expression and stimulating expression of HOXA genes including HOXA7 and HOXA9. Both TET1 and HOXA9 suppress breast tumor growth and metastasis in mouse xenografts. The genes comprising the HMGA2-TET1-HOXA9 pathway are coordinately regulated in breast cancer and together encompass a prognostic signature for patient survival. These results implicate the HMGA2-TET1-HOX signaling pathway in the epigenetic regulation of human breast cancer and highlight the importance of targeting methylation in specific subpopulations as a potential therapeutic strategy. E pigenetic changes play an important role in cancer progression as well as development (1). Recent studies indicate that DNA demethylation can be catalyzed by a class of methylcytosine dioxygenases termed the ten-eleven translocation (TET) family (2-5). TET1 promotes DNA demethylation by catalyzing conversion of 5-methylcytosine (5mC) primarily to 5-hydroxymethylcytosine (5hmC) as well as 5-formylcytosine or 5-carboxylcytosine (3, 5). The modified cytosines are then removed through active or passive mechanisms (2-6). While TET1 is highly expressed in embryonic stem (ES) cells (5, 7-10), loss of TET1 protein and decreased 5hmC levels have been recently shown in solid tumors relative to normal epithelial cells (2, (11) (12) (13) (14) . However, the mechanism by which TET1 is suppressed in solid tumors has not been identified. Furthermore, the downstream targets by which TET1 regulates growth and metastasis in cancer are largely unknown.
The ten-eleven translocation (TET) family of methylcytosine dioxygenases initiates demethylation of DNA and is associated with tumorigenesis in many cancers; however, the mechanism is mostly unknown. Here we identify upstream activators and downstream effectors of TET1 in breast cancer using human breast cancer cells and a genetically engineered mouse model. We show that depleting the architectural transcription factor high mobility group AThook 2 (HMGA2) induces TET1. TET1 binds and demethylates its own promoter and the promoter of homeobox A (HOXA) genes, enhancing its own expression and stimulating expression of HOXA genes including HOXA7 and HOXA9. Both TET1 and HOXA9 suppress breast tumor growth and metastasis in mouse xenografts. The genes comprising the HMGA2-TET1-HOXA9 pathway are coordinately regulated in breast cancer and together encompass a prognostic signature for patient survival. These results implicate the HMGA2-TET1-HOX signaling pathway in the epigenetic regulation of human breast cancer and highlight the importance of targeting methylation in specific subpopulations as a potential therapeutic strategy. E pigenetic changes play an important role in cancer progression as well as development (1) . Recent studies indicate that DNA demethylation can be catalyzed by a class of methylcytosine dioxygenases termed the ten-eleven translocation (TET) family (2) (3) (4) (5) . TET1 promotes DNA demethylation by catalyzing conversion of 5-methylcytosine (5mC) primarily to 5-hydroxymethylcytosine (5hmC) as well as 5-formylcytosine or 5-carboxylcytosine (3, 5) . The modified cytosines are then removed through active or passive mechanisms (2) (3) (4) (5) (6) . While TET1 is highly expressed in embryonic stem (ES) cells (5, (7) (8) (9) (10) , loss of TET1 protein and decreased 5hmC levels have been recently shown in solid tumors relative to normal epithelial cells (2, (11) (12) (13) (14) . However, the mechanism by which TET1 is suppressed in solid tumors has not been identified. Furthermore, the downstream targets by which TET1 regulates growth and metastasis in cancer are largely unknown.
High mobility group AT-hook 2 (HMGA2), a chromatinremodeling factor (15) , binds to AT-rich regions in DNA, altering chromatin architecture to either promote or inhibit the action of transcriptional enhancers. HMGA2 is highly expressed in ES cells but is generally low or lacking in normal somatic cells. Interestingly, HMGA2 is highly expressed in most malignant epithelial tumors, including breast (16), pancreas (17) , oral squamous cell carcinoma (18) , and non-small-cell lung cancer (19) . HMGA2 overexpression in transgenic mice causes tumor formation, whereas Hmga2-knockout mice have a pygmy phenotype indicative of a growth defect (20) . We have reported that HMGA2 promotes tumor invasion and metastasis in breast cancer in part through regulation of prometastatic genes, including Snail, osteopontin, and CXCR4 (21, 22) .
To systematically identify critical downstream mediators of HMGA2 that regulate invasion and metastasis, we performed gene expression array analysis by knocking down HMGA2 in breast cancer cells. Here we show that TET1 is an important effecter of HMGA2 in breast cancer. We further show that TET1 regulates homeobox A (HOXA) genes, including HOXA7 and HOXA9. Both TET1 and HOXA9 suppress breast tumor growth and metastasis. Our study reveals a regulatory pathway that stratifies breast patient survival.
Results
TET1 and HOX Gene Expression Are Dramatically Induced upon Depletion of HMGA2 in both Invasive Human Breast Cancer Cells and MMTV-Wnt1
Mouse Breast Tumors. Gene expression arrays were conducted using two invasive human breast cancer cell lines expressing either HMGA2 shRNA or control scrambled shRNA (SCR sh): 1833, a bone-tropic derivative of the human breast cancer cell line MDA-MB-231 (23) , and MDA-MB-436. We found a dramatic induction of HOX genes, particularly at the HOXA loci in the more invasive 1833 cells ( Fig. 1 A-C and Fig. S1 ). The HOX genes comprise four clusters (A, B, C, and D) located on different human chromosomes. This transcriptional factor family with 39 members controls posterior-anterior patterning during embryogenesis and the development of specific organs (reviewed in ref. 24) . We validated the induction of HOXA gene expression including HOXA4, HOXA5, HOXA6, HOXA7, HOXA9, and HOXA11 in HMGA2-depleted 1833 cells (Fig. 1 D, F, and G) .
Among the other genes induced by HMGA2 depletion was TET1 (Fig. 1A and Fig. S1 ). We confirmed that HMGA2 is a negative regulator of TET1 in 1833 cells by quantitative RT-PCR (qRT-PCR) and immunoblotting (Fig. 1 E and G) . Consistent with increased TET1 expression, we observed elevated 5hmC levels in HMGA2-depleted 1833 cells (Fig. 1H) . We also observed similar induction of TET1 and HOXA gene expression following HMGA2 depletion by shRNA in MDA-MB-436 cells, although the effects were not as robust, consistent with their relatively higher basal levels of TET1 and HOXA protein and the less invasive phenotype of these cells (Fig. S2 A-D) . Consistent with these observations, analysis of gene expression in a cohort of 75 human breast tumors (25) showed a significantly negative correlation between HMGA2 and TET1 expression (Fig. S2E ), and this relationship existed in both estrogen receptor (ER)-negative ( Fig. S2F ) and ER-positive (Fig. S2G ) patient subpopulations.
To validate the regulation of TET1 and HOXA genes by HMGA2 in vivo, we used an MMTV-Wnt1 transgenic mouse model for breast cancer. Deletion of Hmga2 by crossing MMTVWnt1 mice with Hmga2-specific knockout mice reduced tumor incidence (26) and decreased tumor cell proliferation as assessed by immunostaining of antigen Ki67 (Fig. S3 ). Analysis by qRT-PCR or immunohistochemistry showed a strong induction of Tet1, 5hmC, and Hoxa gene expression including Hoxa9 and Hoxa7 in tumors from the MMTV-Wnt1/Hmga2 −/− mice ( Fig. 1 I and J) . Moreover, expression of HMGA2 in both 1833 and MDA-MB-436 cells inhibited TET1 expression (Fig. S4) . These results indicate that induction of TET1 by depletion of HMGA2 is not an off-target effect and raise the possibility that loss of HMGA2 suppresses breast tumor growth by inducing TET1 and HOXA genes. Because the Tet1 protein may bind directly to its own promoter region as suggested by the ChIP-sequencing (ChIP-seq) data for Tet1 in mouse ES cells (9, 10, 27, 28) , we investigated whether TET1 was also involved in regulating its own expression in human breast cancer cells. Conventional ChIP assays using 1833 cells expressing TET1 or vector control showed that TET1 bound to its own promoter region ( Fig. 2A) . Consistent with increased expression of TET1, ChIP assays also showed that 1833 cells expressing TET1 exhibited increased binding of H3K4Me3, a histone marker for transcriptional activation, to the TET1 promoter region ( Fig. 2A) . Furthermore, because TET proteins are typically involved in DNA demethylation pathways (2-5, 29, 30), we analyzed the effect of TET1 on the methylation status of its own promoter regions. Our DNA methylation-specific digestion combined with qPCR showed that ∼70% of the TET1 promoter region within ± 1 kb from the transcription start site (TSS) in the parent 1833 cells contained methylated CpG islands, whereas the fraction decreased to 9% following HMGA2 depletion (Fig. 2B) . Similarly, bisulfite sequencing within the same region of the TET1 promoter showed an increase in demethylated CpGs from 38% in 1833 cells to 86% in HMGA2-depleted cells (Fig. 2C) . The 1833 cells treated with 5-azacytidine, a demethylation reagent that inhibits DNMTs, also showed an increase in TET1 expression (Fig. 2D) . Together, our results suggest that HMGA2 depletion in 1833 cells causes extensive (9, 10, 27, 28) . To investigate whether TET1 is an upstream regulator of the HOXA cluster in human breast cancer cells, we transfected HMGA2-depleted 1833 cells with TET1 siRNA and observed a significant decrease in HOXA gene expression and 5hmC levels along with decreased TET1 expression ( Fig. 3 A and B) . Conversely, ectopic expression of TET1 in the parent 1833 cells dramatically increased HOXA9 expression and 5hmC levels ( Fig. 3 C and D) .
To test whether TET1 can regulate HOXA gene expression in vivo, we stably transduced 1833 cells with an inducible Tet1 expression vector. Cells were orthotopically injected into the mammary fat pad of mice. qRT-PCR and immunohistochemistry analysis of the mouse xenografts after 6 wk of treatment with doxycycline showed a dramatic induction of Tet1 and HOXA9 expression ( Fig. 3 E and F) , as well as increased 5hmC levels (Fig. 3F) . Gene expression analysis in a cohort of 54 human breast tumors (25) also showed a strong positive correlation between TET1 and HOXA gene expression (Fig. 3G) .
We next investigated whether the induction of HOXA gene expression could also be attributed to direct binding of TET1 and subsequent demethylation of the HOXA promoter regions. Our ChIP-qPCR assays confirmed that TET1 and H3K4Me3 also bound to the HOXA gene promoter regions (Fig. 4 A and B) . Our DNA methylation-specific digestion combined with qPCR assay showed that, in the parent 1833 cells, only a small fraction of the promoter region of the HOXA4-A11 genes lacked methylation (Fig. 4C) , accounting for the low expression of HOXA transcripts; by contrast, HMGA2 depletion caused dramatic loss of methylation at the HOXA gene loci (Fig. 4C) . Bisulfite sequencing of the 14 CpGs near the HOXA7 TSS showed that only 4% were unmethylated, whereas HMGA2 depletion caused >80% demethylation (Fig. 4D) . Similarly, bisulfite sequencing of the 15 CpGs in the upstream 1-kb locus of the HOXA9 promoter showed that only 5% of the CpG sites were unmethylated, whereas unmethylated CpGs increased to 91% upon loss of HMGA2 in 1833 cells (Fig. 4E) . The 1833 cells treated with 5-azacytidine to demethylate DNA also showed a dramatic increase in HOXA7 and HOXA9 expression (Fig. 4 F and G) . These results suggest that TET1 binds directly to the HOXA promoter regions and contributes to local demethylation, inducing activating histone binding and gene transcription in breast cancer cells. To assess the pathological significance of this HMGA2/TET1/ HOXA signaling cascade, we determined the effect of manipulating Table S3 for patient information). Correlations were determined by Pearson's correlation coefficient. P value was determined by Student t test. (A-E) GAPDH served as normalization control. Data are means ± SEM; n = 3. **P < 0.01; ***P < 0.001.
these genes on cell invasion. HMGA2 depletion in 1833 cells decreased cell invasion (Fig. 5A) ; this effect was reversed in part by siRNA depletion of TET1, HOXA9, or HOXA7 (Fig. 5 B and C and Fig. S5 I-K) . The 1833 cells treated by demethylation reagent 5-azacytidine or decitabine showed a similar decreased cell invasion and a partial rescue in invasion followed by siRNA depletion of HOXA9 (Fig. 5D and Fig. S5 A-C and E-G) . These data are consistent with a previous study showing that HOXA9 is a breast cancer inhibitor (31) . Together, our results reveal a signaling cascade whereby HMGA2 promotes breast cancer cell invasion in part through inhibition of TET1-mediated demethylation and HOXA gene expression.
Both TET1 and Its Target, HOXA9, Suppress Breast Tumor Growth, Intravasation, and Metastasis. To determine whether TET1 or HOXA9 can reverse the tumorigenic phenotype in breast cancer cells transformed by HMGA2, we injected 1833 cells expressing inducible Tet1 or HOXA9 into the mammary fat pad of mice followed by doxycycline treatment and tested their effect on xenograft tumor growth. Consistent with our in vitro observation (Figs. S5D and S6 A-C) , induced expression of Tet1 (Fig. 3 E and  F) or HOXA9 (Fig. S6 D and E) significantly suppressed xenograft tumor growth (Fig. 5 E-G) and tumor cell proliferation ( Fig. 5 H and I) .
To test TET1 or HOXA9 regulation of invasion in vivo, we determined their effect on tumor cell intravasation from a primary site in a murine orthotopic model. The 1833 cells expressing inducible Tet1 or HOXA9 were injected into the mammary fat pad of mice. After 6 wk of treatment with doxycycline, cells isolated from the blood were lysed and analyzed for human (tumor) or mouse (control) GAPDH transcripts. qRT-PCR analysis showed that both TET1 and HOXA9 significantly inhibited tumor cell intravasation ( Fig. 5 J and K) .
Because HMGA2 depletion suppresses breast tumor cell bone metastasis (21, 22) , we determined whether its downstream effecters TET1 and HOXA9 similarly inhibit tumor metastasis. Luciferase-labeled 1833 cells expressing inducible Tet1 or HOXA9 were injected into the left ventricle of mice that were subsequently treated with doxycycline. After 3 wk, mice were imaged for luciferase activity. TET1 or HOXA9 expression caused a dramatic decrease in bone metastasis (Fig. 5 L and M) and a significant increase in overall survival rate ( Fig. 5N and Fig. S6 F-H) .
HMGA2/TET1/HOXA9 Regulate a Common Set of Important Genes and Encompass a Prognostic Signature for Patient Survival. To identify and compare target genes of HMGA2, TET1, and HOXA9, we performed additional microarray assays for cells expressing induced TET1 and HOXA9. Compared with the parental 1833 cells, there were 1,012; 7,220; and 7,132 genes differentially expressed [P < 0.05; false discovery rate (FDR) < 0.05; and fold change > 1.25) upon HMGA2 depletion, TET1 induction, or HOXA9 induction, respectively (Fig. 6A) . Interestingly, >60% of the genes differentially regulated by TET1 or HOXA9 were the same (4,510 genes; Fig. 6A ), indicating that HOXA9 is a major downstream effecter of TET1. There were 214 genes that overlapped among all three sets, including 144 up-regulated and 70 down-regulated genes ( Fig. 6A and Table S1 ). Gene annotation enrichment analysis (Database for Annotation, Visualization and Integrated Discovery) (32) indicated that the 144-gene upregulated set was enriched in genes that have functions such as binding, catalytic activity, transcription regulator activity, and developmental processes, whereas the 70-gene down-regulated set was enriched in genes related to epithelial cell proliferation (P = 0.041) and the extracellular matrix (P = 0.0077) (Table S2) . Gene set enrichment analysis (33) indicated that the down-regulated set was also enriched in genes that promote tumor growth and comprise metastasis signatures, such as CCL2, EFEMP1, IL7R, PPAP2B, and STX3 (34) . This pattern of gene regulation is consistent with a role for TET1 through its effecter HOXA9 in the suppression of breast tumor growth and metastasis.
These data illustrate a signaling cascade in human breast cancer progression, by which expression of the oncogene HMGA2 leads to TET1 suppression. Because TET1 binds and demethylates itself as well as HOXA genes, including HOXA7 and HOXA9, decreased TET1 causes further inhibition of TET1 in addition to loss of HOXA gene expression. Suppression of TET1 and HOXA9 then enables expression of genes that promote breast tumor growth and metastasis (Fig. 6B) . When considered individually, gene expression of HMGA2, TET1, HOXA7, or HOXA9 does not significantly predict survival in a heterogeneous group of breast cancer patients (Fig. 6 C, Left and I, Left) . By contrast, Kaplan-Meier analysis using the complete HMGA2-TET1-HOXA pathway (HMGA2 high and TET1/HOXA9/7 low vs. HMGA2 low and TET1/HOXA9/7 high) or a combination of HMGA2 and HOXA genes was able to stratify patients and predict survival (Fig. 6 C, Right and I, Right). There are no significant differences in the composition of cancer subtypes between the two stratified groups of patients (Table S3 ), suggesting that this regulatory mechanism exists in a variety of breast cancer subtypes.
Discussion
We identify here not only an important upstream regulator (HMGA2) of TET1, but also a previously undescribed downstream regulatory pathway for TET1 involving HOXA genes; in addition, we provide compelling evidence that TET1 and HOXA9 play an important role not only in breast tumor invasion and growth, but also in metastasis through commonly regulated genes. Because HMGA2 is a genomic architectural factor, we do not exclude the possibility that HMGA2 might be able to regulate TET1 expression by direct binding to the TET1 promoter or by alteration of its chromatin structure. Nonetheless, a recent investigation of HMGA2 binding sites in HCT116 cells that highly express HMGA2 protein showed only 49 binding sites (35) . None of them are even close to the genomic locus of TET1 gene. Thus, it is very likely that HMGA2 regulates TET1 expression indirectly via other mediators. Table S3 for patient information). Patients were stratified for survival using HMGA2, TET1, HOXA9, HOXA7, or the complete pathway as indicated. (Right) Red line, high HMGA2 and low TET1/HOXAs (n = 34); blue line, low HMGA2 and high TET1/HOXAs (n = 35); P, χ 2 P value.
While this work was under completion, it was reported that TET1 inhibits growth and metastasis in prostate and breast cancer (36) . In that report, TET1 was shown to inhibit invasion in culture in part through tissue inhibitors of metalloproteinases (TIMPs) (36) . By contrast, we did not observe significant induction of TIMP expression by TET1. Instead, we identify a group of genes commonly altered by HMGA2 depletion or induction of either TET1 or HOXA9, including a subset of induced genes that promote development and a subset of inhibited genes that promote cell proliferation, consistent with a role for TET1/HOXA9 in suppression of breast tumor growth and metastasis.
The TET1/HOXA9 signaling pathway that we identify here also highlights the importance of cell context in determining the pathological function of TET1. In contrast to our results for breast cancer, the mixed-lineage leukemia-TET1 fusion protein and the HOXA9 protein both promote leukemogenesis (37, 38) . Recently, HOX family members were reported to play key roles in regulating tumorigenesis, including the epithelial/mesenchymal transition, invasion, and apoptosis (24) . Highly methylated HOXA gene loci have been reported in human breast cancer (39) , although mutations in these genes are not common. Whether these genes function in similar ways or promote different phenotypes is an interesting question that requires further investigation.
Finally, this report identifies a gene signature comprising three mechanistically linked genes (HMGA2, TET1, and HOXA9) that is prognostic for breast cancer survival. This signature has the potential to identify patients harboring breast or other tumors with suppressed TET1/HOXA9 signaling who might benefit from DNA demethylation agents currently used in the clinic.
Materials and Methods
HMGA2-depleted cell lines were generated by lentiviral transduction with HMGA2 shRNA. TET1 and HOXA gene knockdown cell lines were generated by transfection with relative siRNA. Tet1-and HOXA9-inducible expression cells were generated by lentiviral transduction with relative inducible expression vector. Detailed descriptions are in SI Materials and Methods.
